The Manufacturers Life Insurance Company Makes New Investment in Privia Health Group, Inc. $PRVA

Posted by George Bondi on Sep 4th, 2026

The Manufacturers Life Insurance Company bought a new stake in shares of Privia Health Group, Inc. (NASDAQ:PRVA – Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 58,420 shares of the company’s stock, valued at approximately $1,503,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Bayban bought a new position in shares of Privia Health Group in the fourth quarter valued at approximately $26,000. Hantz Financial Services Inc. increased its holdings in Privia Health Group by 456.2% during the 4th quarter. Hantz Financial Services Inc. now owns 1,129 shares of the company’s stock worth $27,000 after acquiring an additional 926 shares during the period. Global Retirement Partners LLC increased its holdings in Privia Health Group by 579.8% during the 4th quarter. Global Retirement Partners LLC now owns 1,584 shares of the company’s stock worth $38,000 after acquiring an additional 1,351 shares during the period. Allworth Financial LP purchased a new stake in Privia Health Group in the 2nd quarter worth approximately $48,000. Finally, Harbor Investment Advisory LLC purchased a new stake in Privia Health Group in the 2nd quarter worth approximately $69,000. 94.48% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Citigroup restated a “buy” rating on shares of Privia Health Group in a research report on Thursday, July 23rd. Zacks Research upgraded Privia Health Group from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 5th. Canaccord Genuity Group set a $32.00 target price on Privia Health Group in a research note on Friday, August 7th. Barclays lowered their price target on Privia Health Group from $25.00 to $24.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 26th. Finally, Weiss Ratings raised Privia Health Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, July 2nd. Eleven research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.00.

Read Our Latest Report on PRVA

Privia Health Group Stock Performance

Privia Health Group stock opened at $20.67 on Friday. Privia Health Group, Inc. has a fifty-two week low of $19.53 and a fifty-two week high of $28.82. The stock has a market cap of $2.64 billion, a P/E ratio of 98.43, a price-to-earnings-growth ratio of 1.63 and a beta of 0.87. The firm’s fifty day moving average price is $24.06 and its 200-day moving average price is $23.16.

Privia Health Group (NASDAQ:PRVA – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.07 by $0.12. The company had revenue of $632.63 million during the quarter, compared to analyst estimates of $597.33 million. Privia Health Group had a net margin of 1.19% and a return on equity of 3.52%. The firm’s quarterly revenue was up 21.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.24 earnings per share. On average, analysts predict that Privia Health Group, Inc. will post 0.27 earnings per share for the current year.

Insider Activity

In other news, Director Matthew Morris sold 53,722 shares of the company’s stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $27.24, for a total value of $1,463,387.28. Following the completion of the transaction, the director directly owned 68,188 shares in the company, valued at approximately $1,857,441.12. This represents a 44.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO David Mountcastle sold 21,275 shares of the stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $27.67, for a total value of $588,679.25. Following the transaction, the chief financial officer owned 164,853 shares in the company, valued at $4,561,482.51. This trade represents a 11.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 327,886 shares of company stock valued at $8,628,256. Corporate insiders own 5.70% of the company’s stock.

Privia Health Group Profile

(Free Report)

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.